Daklinza daclatasvir: Phase III data

The open-label, U.S. Phase III ALLY-3 trial in 152 patients with HCV genotype 3 infection showed that a once-daily oral combination of 400 mg Sovaldi sofosbuvir and 60 mg Daklinza daclatasvir for 12 weeks led to an SVR 12 weeks after the end of treatment in 90% of treatment-naïve patients (n=101) and 86% of treatment-experienced patients (n=51). There were 17 treatment failures comprised of 16 post-treatment relapses and 1 rebound at the end of treatment. There were no viral breakthroughs. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...